Japan childhood vaccine schedule: 11 vaccines by age
For babies (first year): BCG (tuberculosis), Hepatitis B, DTaP / Tdap, Polio (IPV), Hib, Pneumococcal (PCV), Rotavirus, MMR, Varicella (chickenpox), Japanese encephalitis. Click a vaccine for its Japan-specific page and its schedule in every other country.
| Vaccine | Status | Doses & recommended age |
|---|---|---|
| BCG (tuberculosis) · side effects & data | Universal | Dose 1 — 5-8 months |
| Hepatitis B · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 3 months Dose 3 — 7-8 months |
| DTaP / Tdap · side effects & data | Universal | Dose 1 — 3 months (DTaP-IPV (4-in-1)) Dose 2 — 4 months (DTaP-IPV (4-in-1)) Dose 3 — 5 months (DTaP-IPV (4-in-1)) Booster — 18 months (DTaP-IPV (4-in-1)) |
| Polio (IPV) · side effects & data | Universal | Dose 1 — 3 months (IPV (in DTaP-IPV)) Dose 2 — 4 months (IPV (in DTaP-IPV)) Dose 3 — 5 months (IPV (in DTaP-IPV)) Booster — 18 months (IPV (in DTaP-IPV)) |
| Hib · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 3 months Dose 3 — 4 months Booster — 12-15 months |
| Pneumococcal (PCV) · side effects & data | Universal | Dose 1 — 2 months Dose 2 — 3 months Dose 3 — 4 months Booster — 12-15 months |
| Rotavirus · side effects & data | Universal | Dose 1 — 2 months (Rotavirus (oral)) Dose 2 — 3 months (Rotavirus (oral)) Dose 3 — 4 months (Rotavirus (oral)) |
| MMR · side effects & data | Universal | Dose 1 — 12 months (MR (measles-rubella)) Dose 2 — 5-6 years (MR (measles-rubella)) |
| Varicella (chickenpox) · side effects & data | Universal | Dose 1 — 12-15 months Dose 2 — 18-24 months |
| Japanese encephalitis · side effects & data | Universal | Dose 1 — 6 months Dose 2 — 7 months Dose 3 — 9 months Booster — 4 years |
| HPV · side effects & data | Universal | Dose 1 — 12-16 years Dose 2 — 1 month after dose 1 Dose 3 — 6 months after dose 1 |
Japan vaccine schedule vs. the United States
Japan and the United States share 9 routine vaccines. Japan also routinely gives BCG (tuberculosis), Japanese encephalitis, which the U.S. does not. The U.S. routinely gives Hepatitis A, Meningococcal, Influenza (flu), COVID-19, which Japan does not.
| Vaccine | Japan first dose | U.S. first dose | Doses |
|---|---|---|---|
| Hepatitis B | 2 months | Birth | 3 vs 3 doses |
| DTaP / Tdap | 3 months | 2 months | 4 vs 5 doses |
| Polio (IPV) | 3 months | 2 months | 4 vs 4 doses |
| Hib | 2 months | 2 months | 4 vs 4 doses |
| Pneumococcal (PCV) | 2 months | 2 months | 4 vs 4 doses |
| Rotavirus | 2 months | 2 months | 3 vs 3 doses |
| MMR | 12 months | 12-15 months | 2 vs 2 doses |
| Varicella (chickenpox) | 12-15 months | 12-15 months | 2 vs 2 doses |
| HPV | 12-16 years | 11-12 years | 3 vs 2 doses |
In the Japan schedule but not the routine U.S. schedule: BCG (tuberculosis), Japanese encephalitis.
In the routine U.S. schedule but not Japan's: Hepatitis A, Meningococcal, Influenza (flu), COVID-19.
Why Japan's schedule looks the way it does
Schedules differ mostly because disease burden and health-system conditions differ. WHO/UNICEF estimates of how many children actually receive each vaccine, and the diseases' reported incidence, explain most of the choices below.
- Tuberculosis: 9.8 new cases per 100,000 people per year (2024) — about 3× the U.S. rate. BCG is given to every newborn nationwide. BCG mainly protects young children from severe TB (meningitis, miliary TB), so countries with high TB incidence give it at birth and low-incidence countries reserve it for risk groups.
- Measles: 2.2 reported cases per million people (2025). Two-dose coverage is 95%; sustained elimination needs roughly 95% coverage with both doses, which is why schedules add or move the second dose when coverage or outbreaks change.
- Hepatitis B birth dose: not part of the WHO-reported universal schedule here. A birth dose matters most where mothers commonly carry hepatitis B, because infection at birth becomes chronic in most infants; countries with low carriage and universal prenatal screening often start hepatitis B vaccination later or target only exposed newborns.
Coverage: share of children who received each vaccine (WHO/UNICEF estimates)
| Vaccine | Japan | United States |
|---|---|---|
| BCG (TB) | 98% (2025) | not reported |
| DTP dose 1 | 91% (2025) | 98% (2025) |
| DTP dose 3 | 91% (2025) | 94% (2025) |
| Measles dose 1 | 92% (2025) | 92% (2025) |
| Measles dose 2 | 95% (2025) | 95% (2025) |
| Polio (IPV series) | 98% (2025) | 93% (2025) |
| Hep B birth dose | not reported | 75% (2025) |
| Hep B dose 3 | 95% (2025) | 93% (2025) |
| Hib dose 3 | 96% (2025) | 92% (2025) |
| Pneumococcal (PCV) | 96% (2025) | 84% (2025) |
| Rotavirus (complete) | 94% (2025) | 77% (2025) |
| HPV dose 1, girls | 49% (2025) | 73% (2025) |
Source: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and WHO reported incidence, via the WHO Immunization Data portal; TB incidence from the WHO Global Health Observatory (indicator MDG_0000000020). Retrieved 2026-10-09. "Not reported" usually means the vaccine is not in the universal schedule. Polio is the completed inactivated-polio series (IPVC).
Other Asia-Pacific countries
Australia · Indonesia · Philippines · South Korea · Vietnam · all 31 countries